Ensysce Biosciences - ENSC Stock Forecast, Price & News

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Ensysce Biosciences Stock Down 5.9 %

Shares of ENSC Stock traded down $0.03 during trading hours on Thursday, hitting $0.50. 466,886 shares of the company's stock traded hands, compared to its average volume of 1,078,000. The stock's fifty day simple moving average is $0.54 and its two-hundred day simple moving average is $0.91. Ensysce Biosciences has a 12-month low of $0.39 and a 12-month high of $7.00. The stock has a market cap of $18.34 million, a price-to-earnings ratio of -0.39 and a beta of -0.07. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 1.43.

Ensysce Biosciences (NASDAQ:ENSC - Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20). The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $1.10 million. On average, analysts expect that Ensysce Biosciences will post -0.73 EPS for the current year.